Clinical trialsCompany release

Coherus reports 75% confirmed response for tagmokitug combination in first-line oesophageal cancer

🇺🇸 Coherus Oncology, Inc. (CHRS) · Thu 29 Oct 2026

Interim Phase 1b data for the investigational CCR8 antibody, given with toripalimab, show high response rates in a small first-line cohort and no new safety signals.

Coherus Oncology on 28 October released interim results from its TREGCHECK Phase 1b study of tagmokitug, an investigational antibody that targets CCR8. The drug is being tested alongside toripalimab, with or without chemotherapy.

In first-line oesophageal squamous cell carcinoma (ESCC), the confirmed response rate was 75% among eight evaluable patients, based on a data cut-off of 14 October. The cohort is very small, so the figure should be read as an early signal rather than a firm estimate of efficacy.

In second-line ESCC, the company reported durable benefit at the 700 mg dose. It did not provide further detail in the information available to us.

On safety, Coherus said no new signals emerged beyond those already associated with PD-1 inhibitors, across more than 120 patients. The company plans to expand enrolment in both ESCC cohorts. Tagmokitug is not approved by the US FDA or any other regulator.

What it means for your team

  • The data are interim, from an early-phase study with only eight evaluable first-line patients, so they carry considerable uncertainty.
  • Safety reporting so far points to a profile in line with PD-1 inhibitors; pharmacovigilance teams will want to see fuller data as the cohorts expand.
  • Tagmokitug remains investigational, with no regulatory approval anywhere, so market-access planning is premature.
  • Planned expansion of both ESCC cohorts will determine whether the early response and durability signals hold.

Company's press release (SEC filing): Coherus Oncology, Inc. ↗

Article written by VigiEye from the official source (Coherus Oncology, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →